scholarly journals Renal Failure Associated with Human Polyomavirus BK and Human Adenovirus in a Child with Acute Lymphoblastic Leukaemia

2021 ◽  
Vol 41 (1) ◽  
pp. 30-32
Author(s):  
Vedran Stevanović ◽  
Goran Tešović ◽  
Ernest Bilić ◽  
Maja Pavlović ◽  
Matej Jelić
Keyword(s):  
Renal Failure ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Viral Infections ◽  
Human Adenovirus ◽  
Human Polyomavirus ◽  
Obstructive Nephropathy ◽  
Haemorrhagic Cystitis ◽  
Life Threatening ◽  
Polyomavirus Bk

Immunocompromised patients are susceptible to multiple severe viral infections. This paper describes a 4-year-old boy with newly diagnosed B-cell precursor acute lymphoblastic leukaemia. The 4-year-old patient developed haemorrhagic cystitis, obstructive nephropathy and renal failure due to human polyomavirus BK and human adenovirus co-infection. Cidofovir should be used only in life-threatening cases.

scholarly journals Invasive mucormycosis during treatment for acute lymphoblastic leukaemia—successful management of two life-threatening diseases

2019 ◽  
Vol 28 (5) ◽  
pp. 2157-2161 ◽  
Author(s):  
Andreas Trobisch ◽  
R. Marterer ◽  
G. Gorkiewicz ◽  
S. Flaschberger ◽  
H. Lackner ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Successful Management ◽  
Life Threatening

scholarly journals Haemophagocytic syndrome triggered by acute lymphoblastic leukaemia with t(9;22)(p24; q11.2)

2019 ◽  
Vol 48 (2) ◽  
pp. 030006051987414
Author(s):  
Huiling Chen ◽  
Pengyun Zeng ◽  
Dekui Zhang
Keyword(s):  
Case Report ◽  
Early Diagnosis ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Combined Treatment ◽  
Final Diagnosis ◽  
Janus Kinase ◽  
Haemophagocytic Syndrome ◽  
Threatening Condition ◽  
Life Threatening

Haemophagocytic syndrome (HPS) is a rare and potentially life-threatening condition that requires early diagnosis and prompt combined treatment. This case report describes a male patient with HPS, presenting as acute liver failure, that underwent a thorough evaluation for the cause of his symptoms. A final diagnosis of acute lymphoblastic leukaemia was established more than 2 months after the first presenting symptom appeared. Furthermore, the patient had an unusual chromosomal abnormality with a t(9; 22)(p24; q11.2) translocation, but the reciprocal janus kinase 2-breakpoint cluster region (JAK2-BCR) and BCR-JAK2 fusion transcripts were not be amplified.

scholarly journals Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion

ESMO Open ◽  
2020 ◽  
Vol 5 (5) ◽  
pp. e000977
Author(s):  
André Baruchel ◽  
Patrick Brown ◽  
Carmelo Rizzari ◽  
Lewis Silverman ◽  
Inge van der Sluis ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Expert Panel ◽  
Panel Discussion ◽  
Paediatric Oncology ◽  
Therapeutic Drug ◽  
Childhood Acute Lymphoblastic Leukaemia ◽  
Leukemic Relapse ◽  
Life Threatening ◽  
The Impact

Insufficient exposure to asparaginase therapy is a barrier to optimal treatment and survival in childhood acute lymphoblastic leukaemia (ALL). Three important reasons for inactivity or discontinuation of asparaginase therapy are infusion related reactions (IRRs), pancreatitis and life-threatening central nervous system (CNS). For IRRs, real-time therapeutic drug monitoring (TDM) and premedication are important aspects to be considered. For pancreatitis and CNS thrombosis one key question is if patients should be re-exposed to asparaginase after their occurrence.An expert panel met during the Congress of the International Society for Paediatric Oncology in Lyon in October 2019 to discuss strategies for diminishing the impact of these three toxicities. The panel agreed that TDM is particularly useful for optimising asparaginase treatment and that when a tight pharmacological monitoring programme is established premedication could be implemented more broadly to minimise the risk of IRR. Re-exposure to asparaginase needs to be balanced against the anticipated risk of leukemic relapse. However, more prospective data are needed to give clear recommendations if to re-expose patients to asparaginase after the occurrence of severe pancreatitis and CNS thrombosis.

Sign in / Sign up

Export Citation Format

Share Document